400
Participants
Start Date
October 31, 2005
Primary Completion Date
May 31, 2007
Study Completion Date
May 31, 2007
Lapaquistat acetate and lipid-lowering therapy
Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Lipid-lowering therapy
Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Tucson
Artesia
Jacksonville
Dunwoody
Idaho Falls
Aurora
Chicago
Melrose Park
Naperville
Overland Park
Livonia
Chesterfield
Margate City
Trenton
Cincinnati
Bristol
San Antonio
Richmond
Benešov
Holice V Cechach
Kladno
Mladá Boleslav
Olomouc
Prague
Trutnov
Ústí nad Orlicí
Zlín
Pärnu
Tallinn
Tartu
Helsinki
Hyvinkää
Tampere
Turku
Berlin
Bochum
Chemnitz
Dresden
Frankfurt
Görlitz
Leipzig
Nuremberg
Krakow
Leszno
Lublin
Niemodlin
Ostrowiec Świętokrzyski
Skierniewice
Sroda Wlkp
Starachowice
Warsaw
Zakopane
Banská Bystrica
Bojnice
Bratislava
Lučenec
Prešov
Šamorín
Žilina
Bloemfontein
Cape Town
Durban
Lyttleton
Pretoria
Randburg
Bath
Birmingham
Blackpool
Blantyre
Chippenham
Edinburgh
Glasgow
Harrow
Hinckley
Newport
Nottingham
Woolpit
Lead Sponsor
Takeda
INDUSTRY